I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation multiples are justified by robust growth prospects in FY2025 and FY2026 (likely beyond that as well). Risks include competition from Novo Nordisk and potential pricing pressures, which could impact margins a...
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S NYSE: NVO were likely the hottest medical sector story in 2024. With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. NYSE: LLY was another key pharma player in this new type of treatment for diabetes and obesity.
Some people make it a New Year's resolution to improve their finances by investing in stocks. It's a laudable goal, and to get started, it's crucial to pick stocks that have the tools to perform well for decades to come.
For the last couple of years, the pharmaceutical sector has become infatuated with glucagon-like peptide 1 (GLP-1) agonists used to treat diabetes and help with chronic weight management. While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (LLY 2.45%) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound.
Eli Lilly (LLY 2.45%) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival.
Washington, D.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- The Thurgood Marshall College Fund (TMCF) has received a substantial grant from Lilly Endowment Inc. to increase capacity at the organization and for the historically Black colleges and universities (HBCUs) that are its member schools.
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.